Evidence map›Paper›PMID 38862265›Full record

ArticleJournal of neurology, neurosurgery, and psychiatry2024

Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease.

Ruth Dobson, Katherine Patterson, Reshad Malik, Uttara Mandal, Hina Asif, Ros Humphreys, Michael Payne, Eng O-Charoenrat, Lauren Huzzey, Adam Clare and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, neurosurgery, and psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Lecanemab appropriate use recommendations for clinical practice in the UK.Journal of neurology, neurosurgery, and psychiatry · 2026
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ruth Dobson *Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.ORCID 0000-0002-2993-585X
Katherine Patterson *National Hospital for Neurology and Neurosurgery, London, UK.
Reshad MalikHaringey Memory Service, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Uttara MandalHaringey Memory Service, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Hina AsifHaringey Memory Service, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Ros HumphreysHaringey Memory Service, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Michael PayneHaringey Memory Service, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Eng O-CharoenratHaringey Memory Service, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Lauren HuzzeyEnfield Memory Service, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Adam ClareEnfield Memory Service, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Kate GreenEnfield Memory Service, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Maija MortonBarnet Memory Service, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Catrin SohrabiBarnet Memory Service, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Navreen SinghBarnet Memory Service, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Amirtha PasupathyBarnet Memory Service, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Milan PatelCamden Memory Service, Camden and Islington Mental Health and Social Care Trust, London, UK.
Sam WhitemanCamden Memory Service, Camden and Islington Mental Health and Social Care Trust, London, UK.
Kate MaxminCamden Memory Service, Camden and Islington Mental Health and Social Care Trust, London, UK.
Nicholas BassTower Hamlets Memory Service, East London NHS Foundation Trust, London, UK.
Bhavya GuptaTower Hamlets Memory Service, East London NHS Foundation Trust, London, UK.
Claudia CooperEast London NHS Foundation Trust, London, UK.
Charles MarshallCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.ORCID 0000-0002-8227-2354
Rimona Sharon Weil *Academic Health Science Centre, UCL Partners, London, UK r.weil@ucl.ac.uk.ORCID 0000-0002-5092-6325
Catherine J Mummery *Dementia Research Centre, University College London, London, UK.

Funding

Wellcome Trust W205167/Z/16/Z
6 · The paper itself

Abstract

backgroundDisease-modifying therapies (DMTs) for Alzheimer's disease (AD) have early evidence of efficacy. Widespread delivery of DMTs will require major service reconfiguration. Treatment pathways will need to include triaging for eligibility, regular infusions and baseline and follow-up MRI scanning. A critical step in planning is provision of real-world estimates of patients likely to be eligible for triaging, but these are challenging to obtain.

methodsWe performed a retrospective service evaluation of patients attending five memory services across North and East London and a national specialist cognitive disorders service. We examined the likely proportion of patients who would (1) be referred for triaging for DMTs and (2) potentially be suitable for treatments.

resultsData from a total of 1017 patients were included, 517 of whom were seen in community memory services and 500 in a specialist clinic. In the memory services, 367/517 (71%) were diagnosed with possible AD. After exclusions of those in whom cognitive and frailty scores, MRI contraindications or anticoagulant use indicated they would be unlikely to be suitable, an estimated 32% would be eligible for triaging. In the specialist cognitive clinic, where additional investigations are available, 14% of those seen (70/500) would be potentially eligible for treatment.

conclusionsWhile a sizeable proportion of patients attending memory clinics may be referred for triaging for DMTs for AD, only a minority are likely to be suitable for these, as demonstrated in patients seen in specialist cognitive services. This will need to be considered when designing pathways for DMT delivery.

Indexed as

Alzheimer DiseaseAgedAged, 80 and overEligibility DeterminationFemaleHumansLondonMagnetic Resonance ImagingMaleMiddle AgedPatient SelectionRetrospective Studiesalzheimer's diseaseclinical neurologydementiamemory

Identifiers

PMID38862265
PMCPMC11347253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.